Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the
safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in
relapsed or refractory multiple myeloma patient.